Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS) Horn KDQJM 1998[Apr]; 91 (4): 265-77In recent years, much basic science research has investigated the predisposing factors, initiation, propagation, and resolution of Gram-negative sepsis, endotoxaemic shock, and the newly defined entity of systemic inflammatory response syndrome (SIRS). A major cause of morbidity and mortality in the post-surgical, neonatal, and geriatric hospital population, sepsis has proven itself notoriously resistant to classical modes of therapy, including antibiotics, fluid/pressor and respiratory support. Recently, the widespread nosocomial isolation of new antibiotic-resistant strains of endotoxin-producing bacteria has further complicated management. For these reasons, there is much interest in alternative treatment modalities which focus upon the endotoxin molecule itself and the systemic inflammatory response it provokes via the cytokine, complement, and coagulation cascades. In this review, recent experimental approaches to the therapy of sepsis and SIRS are discussed in light of each step in the complex inflammatory cascade and in comparison to traditional approaches to prevention and therapy of Gram-negative bacteraemia and septic shock.|Antibodies, Monoclonal/therapeutic use[MESH]|Antioxidants/therapeutic use[MESH]|Complement Inactivator Proteins/therapeutic use[MESH]|Cytokines/antagonists & inhibitors/metabolism[MESH]|Endotoxins/pharmacology[MESH]|Humans[MESH]|Leukocytes/drug effects[MESH]|Macrophages/drug effects[MESH]|Phosphodiesterase Inhibitors/therapeutic use[MESH]|Sepsis/immunology/*therapy[MESH]|Systemic Inflammatory Response Syndrome/immunology/therapy[MESH] |
